PEAR - Pear Therapeutics GAAP EPS of -$0.22 in-line revenue of $4.1M misses by $0.24M
- Pear Therapeutics press release ( NASDAQ: PEAR ): Q3 GAAP EPS of -$0.22 in-line.
- Revenue of $4.1M misses by $0.24M .
- "We continue to break down the barriers to patient access for PDTs, evidenced by our increasing payment rate and new coverage decisions. In addition, we’ve taken significant steps to reduce operating expenses in 2023, including the difficult decision to reduce our workforce." - President and CEO Corey McCann
- Reaffirmed 2022 revenue of $14M - $16M and expects 2023 revenue in the range of $27M to $37M.
For further details see:
Pear Therapeutics GAAP EPS of -$0.22 in-line, revenue of $4.1M misses by $0.24M